Igor Stukalin

929 total citations · 1 hit paper
47 papers, 541 citations indexed

About

Igor Stukalin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Igor Stukalin has authored 47 papers receiving a total of 541 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pulmonary and Respiratory Medicine, 27 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in Igor Stukalin's work include Cancer Immunotherapy and Biomarkers (20 papers), Renal cell carcinoma treatment (14 papers) and Lung Cancer Treatments and Mutations (11 papers). Igor Stukalin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (20 papers), Renal cell carcinoma treatment (14 papers) and Lung Cancer Treatments and Mutations (11 papers). Igor Stukalin collaborates with scholars based in Canada, United States and Denmark. Igor Stukalin's co-authors include Daniel Yick Chin Heng, Daniel E. Meyers, Aliyah Pabani, Don Morris, Nimira Alimohamed, Daniel Y.C. Heng, Vishal Navani, Tina Cheng, Michelle L. Dean and Winson Y. Cheung and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer.

In The Last Decade

Igor Stukalin

43 papers receiving 538 citations

Hit Papers

Immune-Related Adverse Events and Survival Among Patients... 2024 2026 2025 2024 20 40 60
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    2024 60 citations Sarah Cook, Daniel E. Meyers et al. JAMA Network Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Igor Stukalin Canada 12 314 278 126 105 90 47 541
Assaf Moore Israel 15 339 1.1× 277 1.0× 62 0.5× 148 1.4× 122 1.4× 52 653
Michal Sarfaty Israel 13 290 0.9× 182 0.7× 74 0.6× 149 1.4× 116 1.3× 46 539
Laura Doni Italy 12 302 1.0× 185 0.7× 71 0.6× 111 1.1× 72 0.8× 43 434
Renjian Jiang United States 16 406 1.3× 220 0.8× 61 0.5× 209 2.0× 151 1.7× 61 689
K C Lakshmaiah India 11 315 1.0× 186 0.7× 105 0.8× 73 0.7× 72 0.8× 28 544
John A. Steinharter United States 13 541 1.7× 431 1.6× 231 1.8× 134 1.3× 161 1.8× 30 778
Marlo Blazer United States 13 386 1.2× 131 0.5× 143 1.1× 111 1.1× 118 1.3× 30 567
R. Corre France 17 541 1.7× 816 2.9× 84 0.7× 102 1.0× 113 1.3× 88 1.0k
Masashi Niwakawa Japan 11 244 0.8× 317 1.1× 183 1.5× 213 2.0× 94 1.0× 37 576
Réza Elaidi France 16 465 1.5× 527 1.9× 295 2.3× 125 1.2× 224 2.5× 34 881

Countries citing papers authored by Igor Stukalin

Since Specialization
Citations

This map shows the geographic impact of Igor Stukalin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor Stukalin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor Stukalin more than expected).

Fields of papers citing papers by Igor Stukalin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Igor Stukalin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor Stukalin. The network helps show where Igor Stukalin may publish in the future.

Co-authorship network of co-authors of Igor Stukalin

This figure shows the co-authorship network connecting the top 25 collaborators of Igor Stukalin. A scholar is included among the top collaborators of Igor Stukalin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Igor Stukalin. Igor Stukalin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Greene, Mallik, et al.. (2025). Closing the loop in colorectal cancer screening: real-world adherence to follow-up colonoscopy after positive mt-sDNA vs FIT/FOBT, stratified by payer type. Current Medical Research and Opinion. 41(9). 1629–1639. 1 indexed citations
3.
Cook, Sarah, Daniel E. Meyers, Igor Stukalin, et al.. (2024). Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors. JAMA Network Open. 7(1). e2352302–e2352302. 60 indexed citations breakdown →
4.
5.
6.
Navani, Vishal, Daniel E. Meyers, Yibing Ruan, et al.. (2023). Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade. Clinical Lung Cancer. 24(3). e152–e159. 2 indexed citations
7.
Stukalin, Igor, Vishal Navani, Yibing Ruan, et al.. (2023). Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. The Oncologist. 28(9). 812–822. 6 indexed citations
8.
Takemura, Kosuke, et al.. (2023). Trends in health care spending on kidney cancer in the United States, 1996–2016. Cancer. 129(14). 2161–2168. 2 indexed citations
9.
Stukalin, Igor, et al.. (2023). Diffuse Jejunal Lipomatosis and Associated Complications. ACG Case Reports Journal. 10(10). e01179–e01179. 1 indexed citations
10.
11.
Stukalin, Igor, Daniel E. Meyers, Daniel Y.C. Heng, et al.. (2023). Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma. JAMA Network Open. 6(6). e2319607–e2319607. 6 indexed citations
12.
Meyers, Daniel E., Igor Stukalin, Vishal Navani, et al.. (2023). Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors. JTO Clinical and Research Reports. 4(4). 100482–100482. 14 indexed citations
13.
Gan, Chun Loo, Igor Stukalin, Daniel E. Meyers, et al.. (2021). Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer. 151. 115–125. 32 indexed citations
14.
Gibson, Adam, Daniel E. Meyers, Michael Dean, et al.. (2021). P16.03 Early Mortality Associated Factors With Immune Checkpoint Inhibition in Real-World Canadian NSCLC Patients. Journal of Thoracic Oncology. 16(3). S348–S348.
15.
Wells, J. Connor, Shaan Dudani, Chun Loo Gan, et al.. (2021). Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. Clinical Genitourinary Cancer. 19(4). 354–361. 11 indexed citations
16.
Stukalin, Igor, Adam Fundytus, Alexander S. Qian, et al.. (2021). Trends and Projections in National United States Health Care Spending for Gastrointestinal Malignancies (1996–2030). Gastroenterology. 162(4). 1098–1110.e2. 14 indexed citations
17.
Wells, J. Connor, Shaan Dudani, Gan Chen, et al.. (2020). Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma. European Urology Open Science. 19. e1105–e1106. 1 indexed citations
18.
Chen, Gan, Daniel E. Meyers, Igor Stukalin, et al.. (2020). 425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents. Annals of Oncology. 31. S1408–S1408. 2 indexed citations
19.
Ribnikar, Domen, Igor Stukalin, Philippe L. Bédard, et al.. (2020). The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. Current Oncology. 28(1). 107–114. 9 indexed citations
20.
Wells, J. Connor, Igor Stukalin, Craig Norton, et al.. (2016). Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology. 71(2). 204–209. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Assaf Moore Breakdown of academic impact, for papers by Michal Sarfaty Breakdown of academic impact, for papers by Laura Doni Breakdown of academic impact, for papers by Renjian Jiang Breakdown of academic impact, for papers by K C Lakshmaiah Breakdown of academic impact, for papers by John A. Steinharter Breakdown of academic impact, for papers by Marlo Blazer Breakdown of academic impact, for papers by R. Corre Breakdown of academic impact, for papers by Masashi Niwakawa Breakdown of academic impact, for papers by Réza Elaidi
Rankless by CCL
2026